Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.54 |
| ▸ | HMGCR | P04035 | 4/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | RHOC | P08134 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
| ▸ | PDE6D | O43924 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543536 | 0.96 | SLCO1B1 (0.53) | SLCO1B1HMGCRABCB11HDAC1HDAC2 | |
| SCHEMBL543237 | 0.94 | SLCO1B1 (0.55) | SLCO1B1HMGCRABCB11HDAC1HDAC2 | |
| SCHEMBL542885 | 0.91 | SLCO1B1 (0.54) | SLCO1B1HMGCRABCB11HDAC1HDAC2 | |
| SCHEMBL16456490 | 0.87 | SLCO1B1 (0.45) | SLCO1B1HMGCRABCB11HDAC1HDAC2 | |
| SCHEMBL542880 | 0.85 | PGR (0.46) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543539 | 0.82 | PPARA (0.50) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL6805916 | 0.82 | PGR (0.43) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL9365103 | 0.80 | HMGCR (0.70) | SLCO1B1HMGCRABCB11HDAC1HDAC2 | |
| SCHEMBL14308638 | 0.79 | HMGCR (0.62) | SLCO1B1HMGCRABCB11HDAC1HDAC2 | |
| SCHEMBL542949 | 0.79 | PGR (0.60) | PPARGPPARAPPARDPGRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250323-B1 | Compounds having hypolipidemic and hypocholesterolemic activities, process for their preparation and pharmaceutical compositions containing them | CADILA HEALTHCARE LTD (IN) | 2014-01-01 | — | — | EP | claimed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | claimed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | claimed |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | LOHRAY BRAJ BHUSHAN (IN) | 2004-09-23 | — | — | US | claimed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | claimed |
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED | 2003-10-23 | — | — | US | claimed |
| EP-1250323-A2 | COMPOUNDS HAVING HYPOLIPIDEMIC AND HYPOCHOLESTEROLEMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LTD. (IN) | 2002-10-23 | — | — | EP | claimed |
| WO-2001053257-A2 | COMPOUNDS HAVING HYPOLIPEDEMIC AND HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LTD. (IN) | 2001-07-26 | — | — | WO | claimed |
| EP-1250323-B1 | Compounds having hypolipidemic and hypocholesterolemic activities, process for their preparation and pharmaceutical compositions containing them | CADILA HEALTHCARE LTD (IN) | 2014-01-01 | — | — | EP | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-6987123-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2006-01-17 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED | 2003-10-23 | — | — | US | disclosed |
| EP-1250323-A2 | COMPOUNDS HAVING HYPOLIPIDEMIC AND HYPOCHOLESTEROLEMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LTD. (IN) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001053257-A2 | COMPOUNDS HAVING HYPOLIPEDEMIC AND HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LTD. (IN) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | SLCO1B1 124/4885HMGCR 313/4885ABCB11 85/4885 |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | SLCO1B1 124/4885HMGCR 313/4885ABCB11 85/4885 |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | SLCO1B1 2889/4885HMGCR 11/4885ABCB11 325/4885 |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | SLCO1B1 127/4885HMGCR 294/4885ABCB11 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.